European drugmakers call for faster trials, more spending to compete with US, China

By Reuters News

By Pushkala Aripaka

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings on Tuesday that the continent's pharmaceutical industry risks losing out to the United States and China.

Cash-strapped European governments have been under pressure for some time from lobby groups and drugmakers to rethink how they attract, nurture, value ​and pay for innovative medicines to avoid falling behind in an increasingly competitive world.

Chairs of nine drugmakers including AstraZeneca AZN.L, GSK GSK.L, Novo NOVOb.CO, Novartis NOVN.S, Roche ROPC.S, Sanofi SASY.PA called on the European Union and member states to boost investment in the industry. The other signatories were the chairs of Boehringer Ingelheim, Chiesi and Ipsen IPN.PA.

"Europe's alarm bells are ringing ... without urgent action, strategic sectors like pharmaceuticals face a 'slow agony' of decline," they said in an open letter published on their companies' websites calling for more fiscal flexibility on healthcare spending.

"European governments must create conditions that attract investment in next-generation medicines before it's too late."

The chairs said about 40% of new therapies never reach European patients, adding that the bloc's share of global drug research and development had fallen to 31% from 43% in 1990. Its share of commercial clinical trials had halved to 9% in the last decade.

The drugmakers' warnings are the latest sign of frustration in boardrooms over European systems and policies that move more slowly than in the US and China, which attract billions of dollars more in pharmaceutical investments.

Europe spends some 1% of GDP on pharmaceuticals, compared with 2% in the United States and 1.8% in China.

Amsterdam-based healthcare lawyer Ron Lanton said that while Europe still has "extraordinary scientific capabilities", companies are increasingly planning around much more aggressive US policies, which have already forced companies to rethink investments, launches and prices.

"Europe's pharmaceutical competitiveness problem is not just about R&D funding. Companies are looking at the entire pathway from clinical trials to reimbursement and patient access when deciding where to put capital."

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.